Similar Articles

Browse Main Topics:

Business
Computers & Electronics
Education & Reference
Entertainment & Leisure
Family & Home
Finance & Investment
Health
Internet
Pets & Animals
Science & Technology
Society, Politics & Culture
Sports & Recreation

Similar Articles

Chemistry World June 4, 2013 Maria Burke	'Legal high' production gathers pace New designer drugs are popping up in Europe at an unprecedented rate, sometimes on the illicit drug market and sometimes as 'legal' alternatives to controlled drugs, according to the latest report by the EU drugs agency.
Reactive Reports Issue 56 Jeffrey Krise	A Basic Approach to Chemotherapy Chemists have found a way to attack malignant cells with an anticancer drug, while sparing healthy cells.
Chemistry World June 8, 2015 Maria Burke	Warnings that proposed UK blanket ban on 'legal highs' casts net too wide Some legal experts and scientists are warning that a proposed blanket ban on so-called 'legal highs' won't tackle the problem and may well hold back research into areas such as neuroscience.
Chemistry World June 12, 2013 Maria Burke	'Scientific censorship' hamstringing psychoactive drug research Legal controls on psychoactive drugs have hindered neuroscience research and the discovery of new treatments for brain disorders in 'one of the most scandalous examples of scientific censorship in modern times', claim researchers.
Chemistry World June 26, 2013 Emma Stoye	UN report warns of global rise in legal highs The latest World Drug Report from the United Nations Office on Drugs and Crime says governments around the world are struggling to cope with a growing number of legal party drugs.
HHMI Bulletin May 2010 Sarah C.P. Williams	Lab-Grown Liver New cell culture system solves problem of growing liver cells.
Chemistry World September 11, 2013 Emma Stoye	Call to overhaul liver toxicity testing Outdated assays for monitoring liver health could have caused dozens of drug candidates to be wrongly scrapped during development, according to new research.
Bio-IT World April 15, 2003 Mark D. Uehling	Target Elimination Industry and FDA scientists turn to databases, applications software, and laboratory chips to move the safest, most effective molecules into clinical trials.
Chemistry World July 11, 2008 Manisha Lalloo	Side-effects study opens up new drug leads Existing drugs could be used to treat a broader range of diseases, according to scientists in Germany and Denmark, who have predicted drug targets by using side-effects data on medication labels.
BusinessWeek November 29, 2004 Carey & Barrett	Lessons From The Vioxx Fiasco What drugmakers, the FDA, doctors, and patients need to do.
The Motley Fool August 25, 2009 Brian Orelli	How to Keep From Losing Your Shirt More side effects for weight-loss drugs -- maybe.
Chemistry World May 15, 2009 Katrina Megget	Tripping over red tape The UK may be moving a step closer to allowing the use of a cannabis-based drug to treat the symptoms of multiple sclerosis
The Motley Fool May 14, 2007 Mike Havrilla	A Weaker Amgen Amgen's stock is trading lower after an FDA panel balked at two anemia drugs.
Chemistry World December 19, 2011 Rebecca Trager	US agencies collaborate to test 10,000 chemicals A high-speed robotic screening system jointly initiated by three key US health agencies began testing more than 10,000 chemical compounds for potential toxicity on 7 December.
Salon.com October 25, 2001 Mark D. Uehling	Free drugs from your faucet How did tiny amounts of nearly every drug under the sun get into our drinking water -- and what are they doing to us?
The Motley Fool January 31, 2007 Brian Lawler	FDA Says Hurray for More Drug Safety The FDA outlines its proposal to increase drug safety. Whatever the FDA does, pharmaceutical investors should hope that its renewed interest in drug safety doesn't make the already lengthy process of bringing drugs to market any longer.
Chemistry World July 26, 2012 Andrew Turley	New US chemical rules edge nearer A political committee in the US has voted in favor of plans to change the way chemicals are regulated by shifting the burden of proving safety to manufacturers.
Chemistry World December 2009	Column: In the pipeline Is the pharmaceutical industry churning out copycat versions of existing therapies? The author dispels a few myths about 'me-too' drugs
The Motley Fool March 30, 2009 Brian Orelli	Change the Game? Change the Rules! There are ways for investors to get around Obama's plan to lower health care costs. Investing in drug companies in this time of "change" doesn't have to be scary. You've just got to find rule breaker-type drugmakers, because playing by the rules isn't going to cut it anymore.
BusinessWeek April 18, 2005	Making Those Pills Safe For Kids Few medicines get tested on children. Dr. Donald Mattison is pushing to change that.
BusinessWeek June 13, 2005 Catherine Arnst	Biotech, Finally The past 30 years of biological discoveries, insights into the human genome, and exotic chemical manipulation have unleashed a wave of biological drugs, many of them reengineered human proteins.
Chemistry World January 12, 2010 Sarah Houlton	EU to look into chemical mixture exposure The Council of the EU has called on the European Commission to look at whether current legislation adequately assesses the risks from exposure to multiple chemicals from different sources.
The Motley Fool September 12, 2005 M.D. Mitchell	Big Problems for Big Pharma Creating new drugs is never easy, but the companies that excel in three key areas are the ones for investors to watch.
American Family Physician June 1, 2004	Club Drugs-Myths and Risks This article provides a general overview on the topic of club drugs like Ecstasy.
Pharmaceutical Executive January 1, 2006 Kenneth I. Kaitin	Opinion: Memo to von Eschenbach FDA's acting commissioner has an opportunity to clarify a lot of misconceptions about the agency's role in regulating drug safety. His first order of business should be to explain exactly what FDA doesn't do.
The Motley Fool January 26, 2005 Stephen D. Simpson	The Pipeline to Biotech Success Looking at drug R&D is the best way to begin assessing biotech companies as possible investment opportunities.
BusinessWeek September 5, 2005	Putting the FDA Out Front Deputy Commissioner Dr. Janet Woodcock explains how the agency has led the drive for personalized medicine.
Managed Care April 2004 John Carroll	$50M for Drug Comparisons Could Produce Valuable Results The Medicare amendment adopted late last year contains a provision that could help P&T committees, not to mention consumers, evaluate competing drugs.
Chemistry World April 30, 2014 Emma Stoye	New Zealand in legal highs U-turn Politicians in New Zealand have decided to ban designer drugs from sale in the country, reversing an earlier decision to approve low risk drugs while new laws are put in place.
BusinessWeek December 13, 2004 John Carey	How To Prevent Another Vioxx The tragedy should spur Congress and the FDA to improve the safety of new drugs.
Reason April 2001 Ronald Bailey	Goddamn the Pusher Man Why does everybody seem to hate the pharmaceutical industry?
The Motley Fool September 9, 2004 Charly Travers	The Case for Drug Stocks The reports of the drug industry's death are greatly exaggerated.
Salon.com February 16, 2001 Dawn MacKeen	Just say no to DARE America's school-based drug prevention program gives in to critics' pressure.
Chemistry World January 11, 2012 Hayley Birch	Drive towards detecting drugs at the roadside The UK government is setting up an advisory panel that will assess the feasibility of roadside testing for drug driving, similar to testing for drunk driving.
The Motley Fool April 21, 2009 Brian Orelli	Reworking the Broken R&D Model When it comes to drug development, it's becoming increasingly clear that competition isn't always the best thing for the industry. Collaborations will help bring drugs to the market more cheaply.
The Motley Fool October 3, 2007 Brian Orelli	Big Pharma Loves Your Liver Three big pharma companies, AstraZeneca, GlaxoSmithKline, and Roche, are funding a stem-cell consortium. Investors, take note.
The Motley Fool September 26, 2007 Brian Orelli	4 Platform Drugmakers to Watch Platform drugmakers have the potential to develop multiple drugs for a company. Let's take a look at four companies with good prospects: Abraxis BioScience... DURECT... Halozyme... Flamel Technologies...
Salon.com April 20, 2001 Arianna Huffington	The drug companies' racket Pharmaceutical giants are finally bending to worldwide public pressure on AIDS drugs, but we're still victims of their profiteering...
Managed Care July 2005	Cost being equal, consumers prefer older drugs Seven out of 10 consumers would prefer a drug that had been on the market for 10 years or more, compared to a newer drug, even if the copayments were equal. This could be a sign that consumers are more inclined to start using generic medications.
The Motley Fool November 30, 2010 Brian Orelli	A Witty Response to Pharma's R&D Dilemma According to GlaxoSmithKline CEO Andrew Witty, the pharmaceutical industry is a mess. That's the basic gist of his opinion piece in The Economist.
Chemistry World May 2009	Column: In the pipeline Derek Lowe considers what we think we know about how drugs work once we've taken them
The Motley Fool February 27, 2009 Brian Orelli	Can $634 Billion Save the U.S. Health Care System? The good news is that Obama's budget includes a $634 billion down payment on getting insurance for the 48 million uninsured. The bad news is that the president has to pay for that by cutting costs in other areas.
Pharmaceutical Executive March 1, 2007 Patrick Clinton	From the Editor: Incurable Eventually we're going to have lifestyle drugs, powerful ones that will make amazing differences in how we live.
Chemistry World September 18, 2012 James Urquhart	UN report urges chemical industry to clean-up Governments and industry worldwide must address the management of chemicals in order to curtail the escalating heath and environmental risks associated with the widespread production, use and disposal of chemicals, warns the United Nations Environment Program.
Salon.com January 10, 2000 Andy Dehnart	Is being hooked a choice? A new book argues that all addictions are a matter of free will, even heroin and coffee.
Salon.com August 4, 2000 Gary Kamiya	Writing high In "Writing on Drugs," Sadie Plant embarks on a stimulating trip into literature's strangest, smokiest den.
BusinessWeek October 18, 2004 Catherine Arnst	The Waning of the Blockbuster Drug What's promising now are drugs that target niche diseases. That means painful restructuring ahead for Big Pharma
InternetNews October 13, 2004 Roy Mark	Report: The Internet and Drugs Don't Mix It seems an increasing number of Americans are researching drugs online, but safety fears chill buying.
Managed Care October 2007	The Formulary Files Retirees stop taking drugs when annual benefit runs out.
Pharmaceutical Executive July 1, 2005 Patrick Clinton	Playing Doctor Why Congress plans to ban erectile dysfunction drugs from Medicare and Medicaid, and why they shouldn't do it.